Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron’s Antibody Therapy A Lifesaver In Seronegative COVID-19 Patients

Another Landmark For RECOVERY Trial

Executive Summary

Identifying patients who have not mounted an immune response to SARS-CoV2 and treating them with the antibody cocktail cuts risk of death by a fifth.

You may also be interested in...



AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable

While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.

Coronavirus Update: EMA To Update Comirnaty And Spikevax Labels On Cardiac Safety

Comirnaty and Spikevax to get EU label update on cardiac safety, Japanese filing for REGEN-COV, plus vaccine progress for ReiThera and Genexine.

Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed

Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel